Subcellular distribution of desferrioxamine and hydroxypyridin‐4‐one chelators in K562 cells affects chelation of intracellular iron pools
- 1 October 1993
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 85 (2) , 393-400
- https://doi.org/10.1111/j.1365-2141.1993.tb03184.x
Abstract
The interactions of iron chelators with intracellular iron pools have been examined by measuring the subcellular distribution of radiolabelled desferrioxamine (DFO) and the orally active hydroxypyridinone (HPO) chelator 1,2-diethyl-3-hydroxypyridin-4-one (CP94), as well as the ability of these chelators to modify the subcellular distribution of 59Fe delivered by the receptor mediated endocytosis of transferrin. K562 cells were pulsed with 59Fe transferrin and challenged with DFO or CP94 (100 microM IBE) for 20 or 240 min and then subjected to subcellular fractionation. At 20 min there was a significant decrease (P < 0.05) in both lysosomal/particulate 59Fe (75% of control) and cytosolic 59Fe ferritin (50% of control) in cells incubated with CP94, unlike cells treated with DFO where no decrease was observed. By 240 min, in addition to the above, 59Fe accumulation was significantly decreased in the nuclear, mitochondrial, and low molecular weight cytosolic fractions with CP94 (P < 0.05). With DFO a significant decrease in 59Fe in only the lysosomal/particulate and cytosolic ferritin compartments was observed at 240 min (P < 0.05). At this time, however, there was a significant accumulation of both cytosolic low molecular weight 59Fe and cytosolic DFO. The relatively rapid decrease of 59Fe within intracellular compartments seen with CP94 compared to DFO was paralleled by a significantly higher accumulation of CP94 than DFO in nuclear, lysosomal/particulate and low molecular weight cytosolic compartments at 20 min (P < 0.05). These results suggest that transferrin derived endosomal iron may be chelated by HPOs, unlike DFO, due to their faster uptake into these organelles. The more rapid access of HPOs than DFO to certain intracellular iron pools may explain the greater possibility of HPOs to inhibit proliferation of cells in vivo.Keywords
This publication has 30 references indexed in Scilit:
- Long‐term trial with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (L1) I. IRON CHELATION AND METABOLIC STUDIESBritish Journal of Haematology, 1990
- Secretion of neutrophil secondary granules occurs during granulocyte‐macrophage colony stimulating factor induced marginationBritish Journal of Haematology, 1990
- AGRANULOCYTOSIS AND THROMBOCYTOPENIA IN PATIENT WITH BLACKFAN-DIAMOND ANAEMIA DURING ORAL CHELATOR TRIALThe Lancet, 1989
- Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytesBiochimica et Biophysica Acta (BBA) - General Subjects, 1988
- Effect of a specific iron chelating agent on animal models of inflammation.Annals of the Rheumatic Diseases, 1983
- Hepatocyte iron kinetics in the rat explored with an iron chelatorBritish Journal of Haematology, 1982
- Iron mobilization from ferritin by chelating agentsJournal of Inorganic Biochemistry, 1980
- A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agentsBiochimica et Biophysica Acta (BBA) - General Subjects, 1979
- The use of avidin-biotin interaction in immunoenzymatic techniques.Journal of Histochemistry & Cytochemistry, 1979
- Preparation and properties of plasma membrane and endoplasmic reticulum fragments from isolated rat fat cellsBiochimica et Biophysica Acta (BBA) - Biomembranes, 1971